Safe Step Act
- Bill Number
- H.R. 5509
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-19: Referred to the House Committee on Education and Workforce.
- Last Updated
- 2026-07-01T08:09:11Z
AI-Generated Summary
Purpose
The Safe Step Act (H.R. 5509) aims to improve access to prescribed medications for patients in group health plans by requiring health plans and insurers to establish a fair and timely process for exceptions to "step therapy" protocols. Step therapy is a utilization management practice where insurers require patients to try lower-cost or preferred drugs before covering a doctor's recommended drug.
Key Provisions
- Exceptions Process Requirement: Group health plans and health insurance issuers must implement a clear, fast, and transparent system for participants, beneficiaries, or their prescribing doctors to request exceptions to step therapy protocols for covered prescription drugs.
- Criteria for Exceptions: Exceptions must be granted if:
- Prior treatments (including those in the same drug class) were ineffective based on clinical evidence or the patient's records.
- Delaying the requested treatment could cause severe harm, worsen the condition, or lead to irreversible effects.
- Required treatments are contraindicated (medically unsafe) or likely to cause harm.
- Required treatments hinder the patient's ability to work or perform daily activities.
- The patient is stable on the requested drug and previously had coverage for it under another plan.
- Other circumstances as defined by the Secretary of Labor.
- Process Details:
- Allows submission of requests via standard forms (paper or electronic) with minimal required documentation, such as medical history showing failed prior treatments.
- Permits representatives, like advocates, to submit on behalf of patients.
- Information about the process must be included in plan documents and websites.
- Timing for Decisions:
- Standard requests: Response within 72 hours; final decision within 72 hours of any additional information request.
- Expedited requests (for life-threatening situations, severe pain, or loss of function): Response within 24 hours, with final decision as quickly as needed but no later than 24 hours after additional information.
- Duration of Coverage: If approved, coverage for the requested drug lasts at least one year, at the plan's standard cost-sharing rates.
- Reporting Requirements:
- Plans and issuers must report annually to the Secretary of Labor on exception requests, approvals, denials, appeals, and related data (e.g., by medical condition or specialty).
- Contracts with third-party administrators or pharmacy benefit managers (PBMs—entities that manage drug benefits) cannot block access to this data.
- The Secretary must submit summarized reports to Congress annually, including trends in approvals and denials.
- Effective Date: Applies to plan years starting at least 6 months after enactment; final regulations issued within 6 months.
Significant Changes to Existing Law
- Amends the Employee Retirement Income Security Act of 1974 (ERISA) by adding a new section (713A), which previously lacked specific mandates for exceptions to step therapy in employer-sponsored group health plans.
- Introduces federal standards for step therapy exceptions, including defined criteria, timelines, and reporting—previously, such processes varied by state or plan without uniform requirements under ERISA.
- Clarifies that the rules apply to any policy functioning as step therapy, regardless of how it's named.
Potential Impacts
- On Citizens (Patients and Beneficiaries): Could reduce delays in accessing effective medications, potentially improving health outcomes, especially for chronic or serious conditions, but may not eliminate all denials.
- On Government Agencies: The Department of Labor gains oversight responsibilities, including issuing regulations and analyzing reports, which could inform future policy but add administrative workload.
- On Health Plans and Insurers: Increases operational requirements for processing requests and reporting, potentially raising costs for compliance and appeals, though it may standardize practices and reduce litigation over denials.
- No Notable International Relations Impact: The bill focuses on domestic employer-sponsored health coverage and does not address cross-border issues.
Main Stakeholders Affected
- Patients and Beneficiaries: Primary beneficiaries, gaining easier access to prescribed drugs without unnecessary trials of alternatives.
- Prescribing Health Care Providers: Empowered to request exceptions with clinical rationale; must provide supporting evidence.
- Group Health Plans and Health Insurers: Required to build and maintain exception processes, handle reviews, and report data.
- Pharmacy Benefit Managers (PBMs): Impacted through contracts that must allow data sharing for reporting; may need to adjust drug management programs.
- Secretary of Labor and Congress: Responsible for regulations, data collection, and oversight reporting to monitor implementation and effectiveness.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens patient protections under ERISA by mandating due process-like elements (e.g., timely reviews, minimal documentation) for coverage decisions, potentially reducing lawsuits over arbitrary denials; aligns with broader trends in health law emphasizing evidence-based care over cost controls.
- Constitutional: No direct challenges anticipated, as it regulates private employer plans under Congress's commerce clause authority without infringing on free speech or due process rights.
- Political: Promotes bipartisan health access reforms (introduced by members from both parties), but could spark debates on balancing patient rights with insurer cost controls; reporting to Congress may highlight disparities in care, influencing future legislation on drug pricing or utilization management.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (148)
Rep. McBath, Lucy [D-GA-6], Rep. Miller-Meeks, Mariannette [R-IA-1], Rep. Ruiz, Raul [D-CA-25], Rep. Onder, Robert F. [R-MO-3], Rep. Deluzio, Christopher R. [D-PA-17], Rep. Riley, Josh [D-NY-19], Rep. Pingree, Chellie [D-ME-1], Rep. Wittman, Robert J. [R-VA-1], Rep. McBride, Sarah [D-DE-At Large], Rep. Hayes, Jahana [D-CT-5], Rep. Harris, Andy [R-MD-1], Rep. Kennedy, Mike [R-UT-3], Rep. Cleaver, Emanuel [D-MO-5], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Vasquez, Gabe [D-NM-2], Rep. Thanedar, Shri [D-MI-13], Rep. Beatty, Joyce [D-OH-3], Rep. Gottheimer, Josh [D-NJ-5], Rep. Fletcher, Lizzie [D-TX-7], Rep. Dean, Madeleine [D-PA-4], Rep. McClain Delaney, April [D-MD-6], Rep. Walkinshaw, James R. [D-VA-11], Rep. Castor, Kathy [D-FL-14], Rep. Simon, Lateefah [D-CA-12], Rep. Lynch, Stephen F. [D-MA-8], Rep. Mullin, Kevin [D-CA-15], Rep. Peters, Scott H. [D-CA-50], Rep. Scholten, Hillary J. [D-MI-3], Rep. Cohen, Steve [D-TN-9], Rep. Mann, Tracey [R-KS-1], Rep. Mrvan, Frank J. [D-IN-1], Rep. Lee, Summer L. [D-PA-12], Rep. Tokuda, Jill N. [D-HI-2], Rep. Davids, Sharice [D-KS-3], Rep. Loudermilk, Barry [R-GA-11], Rep. Levin, Mike [D-CA-49], Rep. DelBene, Suzan K. [D-WA-1], Rep. Craig, Angie [D-MN-2], Rep. Bonamici, Suzanne [D-OR-1], Rep. Cherfilus-McCormick, Sheila [D-FL-20], Rep. Keating, William R. [D-MA-9], Rep. Castro, Joaquin [D-TX-20], Rep. Gillen, Laura [D-NY-4], Rep. Krishnamoorthi, Raja [D-IL-8], Rep. Davis, Donald G. [D-NC-1], Rep. Correa, J. Luis [D-CA-46], Rep. Luna, Anna Paulina [R-FL-13], Rep. Johnson, Julie [D-TX-32], Rep. Lawler, Michael [R-NY-17], Del. Norton, Eleanor Holmes [D-DC-At Large] and 98 more
Recent Actions
- 2025-09-19: Referred to the House Committee on Education and Workforce.
- 2025-09-19: Introduced in House
- 2025-09-19: Introduced in House
Bill Versions
- Safe Step Act — issued 2025-09-19 — PDF (13 pages)